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COST-EFFECTIVENESS ANALYSIS OF
DALTEPARIN IN PROLONGED PROPHYLAXIS
AGAINST DEEP VEIN THROMBOSIS AFTER HIP
ARTHROPLASTY
Segú JL1, Soto J2
1CAP la Barceloneta, Barcelona, Spain; 2Pﬁzer, S.A, Alcobendas,
Madrid, Spain
OBJECTIVES: Prophylactic dalteparin reduces the 
incidence of deep venous thrombosis (DVT) after hip
replacement. The aim of this analysis is to perform a
pharmacoeconomic evaluation of prolonged (35 day)
versus short (7 day) prophylaxis with dalteparin for this
indication. METHODS: A cost-effectiveness analysis was
carried out by building a decision analytic model. Effec-
tiveness data were taken from a meta-analysis of all clin-
ical trials (CT) of dalteparin in prolonged prophylaxis
after hip replacement. After pooling and analyzing all CT
found, the incidence of DVT was 6.1% with a prolonged
prophylaxis and 15.1% when using a short prophylaxis.
Health care resources utilization with dalteparin was
taken from the aforementioned meta-analysis and a local
expert panel. Only direct medical costs were included in
the model (drug acquisition, length of hospital stay, diag-
nostic procedures and treatment of DVT cases). Drug
acquisition cost data were obtained from ofﬁcial sources
while the rest of the data were taken from a national
Health care cost database. The perspective selected for
this analysis was the National Health Service and the 
time horizon chosen was 35 days, being the maximum
time that patients received dalteparin as prophylaxis.
RESULTS: In two hypothetical cohorts of 500 patients,
424 patients reported no DVT cases in the prolonged pro-
phylaxis group resulting in a cost/patient free of DVT of
€370 whilst 469 patients in the short prophylaxis group
reported no DVT thereby giving a cost/patient free of
DVT of €611. CONCLUSION: This pharmacoeconomic
analysis demonstrates that prolonged prophylaxis with
dalteparin is a more efﬁcient alternative than short pro-
phylaxis, as it presents better clinical results with lower
associated costs and a lower cost/effectiveness ratio.
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HEALTH SYSTEM COSTS OF OUT-OF-HOSPITAL
CARDIAC ARREST IN RELATION TO TIME TO
SHOCK
Van Alem AP, Dijkgraaf MGW, Koster RW
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OBJECTIVES: Widespread use of automated external
deﬁbrillators by policemen and ﬁre ﬁghters in the Nether-
lands may shorten the time to shock in out-of-hospital
cardiac arrest (OHCA). This study assessed the average
health care costs per life saved and the incremental cost-
effectiveness ratios for three different “reduced time to
shock’s cenarios. METHODS: Between January 2000 and
January 2002 all consecutive patients in witnessed OHCA
in Amsterdam, with ventricular ﬁbrillation as initial
rhythm, identiﬁed by the dispatch center, were included.
Each patient’s time to shock was estimated and assigned
to one of 3 categories: <7 minutes (early), 7–12 minutes
(intermediate), and >12 minutes (late). Clinical data and
health care costs were prospectively collected at patient
level for the ﬁrst half-year after collapse. RESULTS: A
total of 308 patients were included. Six-month survival
was 22%. The mean pre-, in-, and post-hospital costs
were €559, €6,870, and €666, respectively. On average,
€28,636 were spent per survivor and €2,384 per non-
survivor. Among patients shocked early (N = 24), 46%
survived, averaging €20,253, whereas 54% died, averag-
ing €2,836. Of the intermediate group (N = 149) 26%
survived, averaging €31,467, and 74% died, averaging
€2,884. Among patients shocked late (N = 135), 13%
survived, averaging €27,781, 87% died, averaging
€1,859. The incremental cost-effectiveness ratios for
reductions of time from late to intermediate, late to early,
and intermediate to early were €37,376, €16,679, and
€3,225 respectively. CONCLUSIONS: Most costs after
OHCA were made in-hospital. Mean costs per survivor
were lowest with the shortest time to shock. Reduced time
to shock scenarios showed incremental health care costs
per life saved, which were well within acceptable societal
limits. It is most efﬁcient to put all effort in optimizing
for shock delivery within seven minutes after the collapse.
Further study should be directed at the program costs of
measures to ensure early shock delivery.
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OBJECTIVES: Coronary heart disease (CHD) is the
single commonest cause of premature death in the UK 
and is a major priority for the NHS. A stochastic 
decision model was developed to establish the cost-
effectiveness of treating new hypercholesterolaemic
patients to European target levels of blood total choles-
terol (TC) and low density lipoprotein-cholesterol (LDL-
C), using either rosuvastatin, atorvastatin, simvastatin,
pravastatin or ﬂuvastatin. METHODS: The model was
used to estimate the proportion of patients reaching target
and the associated costs over a 1-year period from the
perspective of the NHS. The effectiveness of the alterna-
tive statins were modelled using the percentage reductions
in TC and LDL-C principally derived from the Statin
Therapies for Elevated Lipid Levels compared Across
doses to Rosuvastatin (STELLAR) trial (n = 2341).
Second order probability distributions and Monte Carlo
simulations were used to reﬂect parameter uncertainty.
650 Abstracts
Mean estimates of the difference in cost and patients
treated to target (PTT) were used to establish the optimal
adoption decision. The uncertainty surrounding this deci-
sion was characterised by estimating cost-effectiveness
acceptability curves and the associated frontier. Sensitiv-
ity analysis assessed the robustness of the results to alter-
native scenarios including: baseline cholesterol levels,
dosage regimens and the availability of signiﬁcantly dis-
counted generic simvastatin. RESULTS: Rosuvastatin is
demonstrated to dominate (i.e. lower costs and a higher
number of PTT) atorvastatin, simvastatin, and pravas-
tatin. Compared to ﬂuvastatin, the incremental cost per
additional PTT of rosuvastatin was £24 using LDL-C and
£83 using TC. The probability that rosuvastatin is cost-
effective exceeds 95% provided the NHS is prepared to
pay at least £35 per PTT to achieve target LDL-C cho-
lesterol levels (£160 for TC). These results were demon-
strated to be robust to all scenarios examined in the
sensitivity analysis. CONCLUSIONS: The analysis
demonstrates that rosuvastatin is more cost-effective than
the other statins in achieving European cholesterol
targets.
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THERAPY IN THE PREVENTION OF
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OBJECTIVES: Antiplatelet therapy, following acute
stroke, has been shown to have preventative efﬁcacy
against serious vascular events, including: recurrent
stroke, transient ischaemic attack, and myocardial infarc-
tion. We used a Markov model approach to consider 
the relative cost-effectiveness of alternative antiplatelet
therapies compared to standard low-dose aspirin.
METHODS: An existing Markov model was updated
with UK-speciﬁc data on expected health care resource
usage and unit costs, and was used to consider levels of
recurrent stroke-related events, and their associated cost
implications, over periods of time of up to 25-years after
an acute stroke event. Underlying risks were derived from
the placebo-control arm of the ESPS-2 study (Years 1–2
of the model), and the community-based Oxford Com-
munity Stroke Project (Years 3–5 of the model). Beyond
Year 5, risks were based on an age-matched cohort from
the OCSP data. Relative risks for active treatments were
derived from the ESPS-2 study for both Asasantin Retard
and low-dose aspirin, and the CAPRIE study for clopi-
dogrel. Estimates of expected resource usage were based
on feedback on a structured questionnaire survey of UK-
based clinicians. RESULTS: When compared to low-dose
aspirin, Asasantin Retard provided additional beneﬁts
(29 avoided recurrent strokes per 1,000 treated patients
over a 5-year period) for an additional cost of approxi-
mately £66,000 (a cost per avoided stroke of £2,249). A
probabilistic Monte carlo sensitivity analysis based on
background placebo-level risks, relative risk for Asasan-
tin Retard, costs of an acute stroke and costs of long-term
care suggested that a 95% likelihood of the cost per
avoided stroke value falling below £14,000. Asasantin
Retard had lower treatment-related cost and avoided
more recurrent stroke events than clopidogrel in the mod-
elled 5-year analysis. CONCLUSIONS: Our modelled
analysis suggests that Asasantin Retard is a cost-effective
treatment compared to standard low-dose aspirin in
avoiding acute recurrent stroke-related events.
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OBJECTIVE: To estimate the excess cost of stroke in
Sweden, and potential cost offsets by preventing the
occurrence of ﬁrst-ever stroke. METHODS: We adopted
the incidence approach for estimating the present value
of both direct- and indirect costs. Data on mortality,
stroke recurrence and inpatient care were estimated from
a national register of patient data with a 4-year follow-
up period. To estimate costs for social services we used
registered data on living conditions before stroke onset,
and at 3 and 24 months. Costs for outpatient visits, reha-
bilitation, drugs and production losses due to premature
death and early retirement are estimated on the basis of
both published and non-published sources. Lifetime costs
are extrapolated from year ﬁve and for subsequent years
adjusted by age, gender and excess mortality for stroke.
RESULTS: With an incidence of 17,000 ﬁrst-ever strokes
in Sweden (195/100,000 individuals), the total excess
direct and indirect cost of stroke is SEK9.5 billion
(approximately US$1.2 billion or €1.0 billion) in year
2000 prices. About SEK7.4 billion is direct costs and
SEK2.1 billion indirect costs. Half of the direct costs are
costs for social services. The present value direct cost for
an average stroke patient is SEK434,000 (US$54,250 
or €48,740) and the indirect cost is SEK125,000
(US$15,600 or €13,750). CONCLUSIONS: There are
large potential cost offsets both in the health care sector
and in the social service sector if the incidence of ﬁrst-
ever stroke could be reduced.
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